The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. After-hours trades for Fortress Biotech Inc. (FBIO) shows that investor sentiment remained intact, with the stock’s consolidated last price rising by $0.0079, or 0.84%, to $0.945. The Fortress Biotech Inc. has recorded 659 volume in the after hours trading session. The stock was recently discussed on Yahoo Finance as it revealed that Journey Medical Corporation Appoints Joseph Benesch as Interim Chief Financial Officer.
Fortress Biotech Inc. is listed on the NASDAQ as a member of the Healthcare sector and is a part of the Biotechnology industry. At the end of the last regular session, the stock closed at $0.94 and fluctuated between $0.9900 as its day high and $0.9000 as its day low. The current market capitalization of Fortress Biotech Inc. is $108.72M. A total of 0.59 million shares were traded on the day, compared to an average of 393.56K shares.
Additionally, investors take into account insider trades when predicting how a stock will perform. During the recent three months, FBIO has seen 14 BUY and 0 SELL insider trades, representing the acquisition of 4,478,588 and the disposition of 0 shares. Over the last 12 months, there were 16 BUYs and 0 SELLs from insiders. Insiders purchased 4,582,852 shares during that period but sold 0.
In the most recent transaction, ROSENWALD LINDSAY A MD bought 100,000 shares of FBIO for 0.68 per share on Dec 01. After the transaction, the PRESIDENT, CEO & CHAIRMAN now owns 11,730,324 company shares. In a previous transaction on Nov 30, ROSENWALD LINDSAY A MD bought 5,000 shares at 0.56 per share. FBIO shares that PRESIDENT, CEO & CHAIRMAN owns now total 11,630,324.
Among the insiders who bought shares, Jin David acquired of 5,000 shares on Nov 30 at a per-share price of $0.56. This resulted in the Chief Financial Officer holding 1,402,829 shares of FBIO after the transaction. In another insider transaction, ROSENWALD LINDSAY A MD bought 100,000 shares at $0.69 per share on Oct 21. Company shares held by the PRESIDENT, CEO & CHAIRMAN now total 11,625,324.
Though price targets are rarely accurate, they can exert some influence from time to time and were often accepted as valuable by the market. According to analysts who have offered 12-month price targets for FBIO in the last 3 months, the mean price target is $5.10 with high estimates of $6.00 and low estimates of $2.50. In terms of 52-week highs and lows, FBIO has a high of $2.31 and a low of $0.48.
As of this writing, FBIO has an earnings estimate of -$0.27 per share for the current quarter. EPS was calculated based on a consensus of 6 estimates, with a high estimate of -$0.15 per share and a lower estimate of -$0.57. The company reported an EPS of -$0.18 in the last quarter, which was 35.70% higher than expectations of -$0.28.
Balance Sheet Annually/Quarterly
A balance sheet is a report that shows the company’s assets and liabilities. In addition, it shows how much equity investors have invested in the company. Investors can determine the company’s prospects by calculating its financial ratios based on this information.
It may be riskier to trade before market opening and after market closing than during regular market hours. Since issuers often announce critical financial information outside regular trading hours. Extended-hours trading may result in wider spreads for particular securities due to lower liquidity and higher volatility. Currently, 5 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for FBIO is Overweight with a score of 5.00. A total of 5 analysts rated the stock as Buy while 0 rated it as Overweight while 0 rated it as Hold. Among the other participants, 0 thought the stock was Underweight and 0 thought it should be Sold.